Fatigue prevalence in men treated for prostate cancer: A systematic review and meta-analysis
Authors:
- Yu-Hong LuoYLYu-Hong Luo
- Yan-Wei YangYYYan-Wei Yang
- Chang-Fu WuCWChang-Fu Wu
- Chao WangCWChao Wang
- Wen-Juan LiWLWen-Juan Li
- Hong-Chen ZhangHZHong-Chen Zhang
Open Access
- 26 July 2021
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 9 (21) , 5932-5942
Abstract
The side effects of prostate cancer (PCa) treatment are very prominent, with cancer-related fatigue (CRF) being the most common. Fatigue is a distressing symptom that interferes with daily functioning and seriously affects patient quality of life during, and for many years after, treatment. However, compared with other types of cancer, such as breast cancer, little is known about the prevalence of PCa-related fatigue. To determine the prevalence of CRF in patients with PCa. A systematic search of EMBASE, PubMed, Web of Science, Cochrane Library, Chinese National Knowledge Infrastructure, WANFANG DATA, Technology Journal Database and the Chinese Biological Medical Database was conducted up to July 28, 2020. Included studies measured the incidence of PCa-related fatigue and differentiated fatigue outcomes (incidence) between treatment modalities and fatigue assessment times. In our meta-analysis, both fixed and random-effects models were used to estimate the pooled prevalence of PCa-related fatigue. Subgroup analyses were performed using treatment modalities and fatigue assessment times. Publication and sensitivity bias analyses were performed to test the robustness of the associations. Fourteen studies, involving 4736 patients, were eligible for the review. The pooled CRF prevalence was 40% in a total sample of 4736 PCa patients [95% confidence interval (CI): 29-52; P < 0.01; I2 = 98%]. The results of the subgroup analyses showed the prevalence of CRF after androgen deprivation therapy treatment, radical prostatectomy and radiotherapy to be 42% (95%CI: 20-67, P < 0.01, I2 = 91%), 21% (95%CI: 16-26, P = 0.87, I2 = 0%) and 40% (95%CI: 22-58, P < 0.01, I2 = 90%), respectively. The prevalence of acute and persistent fatigue was 44% (95%CI: 25-64; P < 0.01; I2 = 93%) and 29% (95%CI: 25-32; P = 0.30; I2 = 17%), respectively. Our meta-analysis showed that fatigue is a common symptom in men with PCa, especially those using hormone therapy.Keywords
This publication has 39 references indexed in Scilit:
- Cancer in Australia: Actual incidence data from 1991 to 2009 and mortality data from 1991 to 2010 with projections to 2012Asia-Pacific Journal of Clinical Oncology, 2013
- Cancer survival and prevalence in Australia: Period estimates from 1982 to 2010Asia-Pacific Journal of Clinical Oncology, 2013
- Cancer in Australia: Actual incidence and mortality data from 1982 to 2007 and projections to 2010Asia-Pacific Journal of Clinical Oncology, 2011
- Clinically relevant fatigue in recurrence-free prostate cancer survivorsAnnals of Oncology, 2011
- Combined Resistance and Aerobic Exercise Program Reverses Muscle Loss in Men Undergoing Androgen Suppression Therapy for Prostate Cancer Without Bone Metastases: A Randomized Controlled TrialJournal of Clinical Oncology, 2010
- A scoring system for appraising mixed methods research, and concomitantly appraising qualitative, quantitative and mixed methods primary studies in Mixed Studies ReviewsInternational Journal of Nursing Studies, 2009
- Randomized Controlled Trial of Resistance or Aerobic Exercise in Men Receiving Radiation Therapy for Prostate CancerJournal of Clinical Oncology, 2009
- A Brief Intervention for Fatigue Management in Breast Cancer SurvivorsCancer Nursing, 2008
- Cancer-Related Fatigue: The Scale of the ProblemThe Oncologist, 2007
- Randomized Controlled Trial of an Educational Intervention for Managing Fatigue in Women Receiving Adjuvant Chemotherapy for Early-Stage Breast CancerJournal of Clinical Oncology, 2005